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BACKGROUND: The determinants and consequences of pulmonary hypertension after successfully corrected valvular heart 
disease remain poorly understood. We aim to clarify the hemodynamic bases and risk factors for mortality in patients with 
this condition.
METHODS AND RESULTS: We analyzed long-term follow-up data of 222 patients with pulmonary hypertension and valvular heart 
disease successfully corrected at least 1  year before enrollment who had undergone comprehensive hemodynamic and 
imaging characterization as per the SIOVAC (Sildenafil for Improving Outcomes After Valvular Correction) clinical trial. Median 
(interquartile range) mean pulmonary pressure was 37 mm Hg (32–44 mm Hg) and pulmonary artery wedge pressure was 
23 mm Hg (18–26 mm Hg). Most patients were classified either as having combined precapillary and postcapillary or isolated 
postcapillary pulmonary hypertension. After a median follow-up of 4.5 years, 91 deaths accounted for 4.21 higher-than-ex-
pected mortality in the age-matched population. Risk factors for mortality were male sex, older age, diabetes mellitus, World 
Health Organization functional class III and higher pulmonary vascular resistance—either measured by catheterization or ap-
proximated from ultrasound data. Higher pulmonary vascular resistance was related to diabetes mellitus and smaller residual 
aortic and mitral valve areas. In turn, the latter correlated with prosthetic nominal size. Six-month changes in the composite 
clinical score and in the 6-minute walk test distance were related to survival.
CONCLUSIONS: Persistent valvular heart disease–pulmonary hypertension is an ominous disease that is almost universally as-
sociated with elevated pulmonary artery wedge pressure. Pulmonary vascular resistance is a major determinant of mortality 
in this condition and is related to diabetes mellitus and the residual effective area of the corrected valve. These findings have 
important implications for individualizing valve correction procedures.
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The most common cause of pulmonary hyperten-sion (PH) worldwide is left-sided heart disease (LHD),1,2 and valvular heart disease (VHD) is a sig-
nificant cause of this type of PH.3,4 Despite important 
improvements in the timing of valve interventions, long-
standing PH after surgery is still frequent.5 Furthermore, 
as a result of nonestablished mechanisms, PH may 
eventually develop in patients with corrected VHD who 
did not show PH before surgery.6 Understanding the 
physiological bases of persistent VHD-PH would ben-
efit of a comprehensive hemodynamic profiling of pa-
tients with this condition.
Signs of PH by Doppler echocardiography after 
correction of VHD are associated with long-term 
mortality and disability.6–10 Selecting therapeutic 
strategies in group 2 PH requires counterbalancing 
their risks against robust survival indicators of the un-
derlying disease. However, to our knowledge, there 
are no prospective series of patients with unequiv-
ocal persistent VHD-PH studied at late stages after 
the valve correction. Extrapolating outcomes from 
other causes of LHD-PH such as heart failure may 
be misleading because additional risk factors that 
impact pulmonary pressures such as left ventricular 
(LV) systolic and diastolic dysfunction11 may be ab-
sent in corrected VHD.
The present study was designed to assess the he-
modynamic bases of persistent VHD-PH and to iden-
tify catheterization and imaging predictors of survival 
of patients with this condition, studied at least 1 year 
after the primary valvular lesion was successfully cor-
rected. For this purpose, we related long-term survival 
with baseline variables of the SIOVAC (Sildenafil for 
Improving Outcomes After Valvular Correction) trial co-
hort.12 Additionally, we aimed to validate 6-month sur-
rogate end points typically used in prospective clinical 
trials in the field.
METHODS
The data that support this study are available from the 
corresponding author on reasonable request.
Patients and Study Design
SIOVAC was an investigator-driven, multicenter, ac-
ademically sponsored, randomized, double-blind, 
placebo-controlled, parallel clinical trial testing the 
efficacy of sildenafil on 6-month outcomes of pa-
tients with persistent VHD-PH.12 The study was per-
formed in 18 academic hospitals in Spain and the 
Fundación de Investigación Biomédica Hospital 
Gregorio Marañón served as the coordinating center. 
The main results showed that sildenafil was related to 
worse clinical outcomes than placebo at 6 months.12 
Patients were enrolled between May 2008 to 
December 2015, and on September 2019 the sur-
vival status was updated from the electronic records 
or telephonic interview. The investigator drug was in-
terrupted at the end of the 6-month randomization 
period. The study was authorized by the Spanish 
Agency of Medicinal Products and Medical Devices 
and approved by the reference ethic committee and 
the local ethic committees of all participant institu-
tions. All patients provided written informed consent. 
A second approval by the ethics committees was ob-
tained for the purpose of extending follow-up, which 
waived the need for signing a new informed consent. 
The SIOVAC trial is registered with ClinicalTrials.gov 
NCT00862043 and EudraCT 2007-007033-40.
CLINICAL PERSPECTIVE
What Is New?
• Mortality of patients with persistent pulmonary 
hypertension in successfully corrected valvular 
heart disease is high.
• Major risk factors are age, male sex, diabetes 
mellitus, advanced functional class, and high 
pulmonary vascular resistance.
What Are the Clinical Implications?
• Chronically elevated left-sided heart pressures 
play a major role in the development and per-
petuation of persistent valvular heart disease–
pulmonary hypertension.
• Small valve prostheses, particularly in the mitral 
position, show the highest-risk hemodynamic 
profile.
• Thus, preventing the consequences of persis-
tent valvular heart disease–pulmonary hyper-
tension should rely not only on an adequate 
timing of the valve interventions but also on 
avoiding small residual valve areas, particularly 
in men and patients with diabetes mellitus.
Nonstandard Abbreviations and Acronyms
6MWT 6-minute walk test
LHD left-sided heart disease
mPAP mean pulmonary arterial pressure
PAWP pulmonary artery wedge pressure
PH pulmonary hypertension
PVR pulmonary vascular resistance
PSAP pulmonary artery systolic pressure
SIOVAC Sildenafil for Improving Outcomes After 
Valvular Correction
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Patients were screened in outpatient clinics and 
imaging laboratories of participating institutions.12 
In summary, enrollment criteria included echocar-
diographic signs of PH (systolic pulmonary artery 
pressure ≥50 mm Hg as measured by Doppler echo-
cardiography), a successful surgical or percutaneous 
valvular replacement or repair procedure with com-
plete correction of the left-sided heart valve disease 
performed at least 1 year before inclusion, and a stable 
clinical condition. Major exclusion criteria included any 
significant residual prosthesis or native left-sided heart 
valvular dysfunction and a life expectancy <2  years. 
Only patients with a mean pulmonary arterial pressure 
(mPAP) ≥30 mm Hg by right-sided heart catheterization 
were randomized and received the investigation drug. 
However, nonrandomized patients with PH (mPAP be-
tween 20 and 30 mm Hg) underwent an identical fol-
low-up protocol and are also included in the present 
report.
Procedures
All patients underwent clinical, imaging, and cath-
eterization procedures at enrollment. Hemodynamic 
measures during right-sided heart cardiac catheteri-
zation were obtained at baseline and after an acute 
vasoreactivity test with 100  mg of sublingual silde-
nafil.12,13 The diastolic pressure gradient and (mean) 
transpulmonary pressure gradient were calculated 
subtracting the mean pulmonary artery wedge 
pressure (PAWP) from the diastolic and mean pul-
monary artery pressures, respectively. Pulmonary 
vascular resistance (PVR) and pulmonary arte-
rial compliance were calculated as transpulmonary 
pressure gradient/cardiac output and stroke vol-
ume/pulse pressure, respectively. Pulmonary arte-
rial elastance was calculated as systolic pulmonary 
artery pressure/stroke volume.
We used current definitions of PH (mPAP ≥20 mm 
Hg) as well as hemodynamic classification crite-
ria for defining precapillary PH (PAWP ≤15 mm Hg), 
isolated postcapillary PH (PAWP >15  mm Hg and 
PVR  <3 Wood units [WU]), and combined precap-
illary and postcapillary PH (PAWP >15  mm Hg and 
PVR ≥3 WU).14 Patients with a PAWP ≤15 mm Hg but 
PVR  <3  WU were designated as having “high-out-
put” PH. All patients underwent clinical assessment, 
6-minute walk test (6MWT), and Doppler echocar-
diography examinations at baseline and at 3 and 
6 months.
A blinded core laboratory analyzed cardiac im-
ages.12 Mitral and aortic effective valve areas were 
determined by the continuity equation using stroke 
volume values obtained by cardiac catheterization 
divided by their respective valvular Doppler time-ve-
locity integrals. Mitral valve mismatch was defined 
for repaired mitral valves or prostheses in the mitral 
position as an effective valve area index ≤1.2 cm2/m2 
of body surface area, whereas aortic valve mismatch 
was defined as a prosthetic effective valve area 
index ≤0.65 cm2/m2. Blood sampling was performed 
at baseline and 6 months for brain natriuretic peptide 
measurements. All randomized patients stopped the 
investigation product after the 6-month period and 
underwent medical management as per criteria of 
their referring physicians.
End Points
For the extended follow-up period, the primary end 
point of the present investigation was all-cause mortal-
ity and the secondary end point was cardiovascular 
mortality, which included all cardiac causes, stroke, 
and fatal hemorrhagic complications. The primary 
end point of the SIOVAC randomized clinical trial 
was change (improved, unchanged, or worsened) in 
the clinical composite score, in terms of: (1) death or 
hospital admission for heart failure, (2) change in func-
tional class, and (3) patient global self-assessment at 
6 months.12,15 Secondary end points of the clinical trial 
were 6-month changes in the 6MWT distance, brain 
natriuretic peptide levels, and Doppler-derived systolic 
pulmonary artery pressure. The primary and second-
ary end points of the randomized clinical trial were 
validated against the primary end point of the present 
long-term study.
Figure 1. Enrollment of the study cohort.
The confirmatory catheterization procedure excluded pulmonary 
hypertension (PH) (mean pulmonary arterial pressure [mPAP] 
<20  mm  Hg) in 3 patients, and 6 were lost to follow-up. 
Consequently, 222 patients with catheterization-confirmed PH 
and complete follow-up data are the basis of this report. SIOVAC 
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Table 1. Baseline Characteristics of the Study Cohort
Not Randomized Randomized Full Cohort
n= 27 n= 195 N= 222
Age, y 71 (66–76) 72 (66–77) 72 (66–77)
Women, n (%) 20 (74) 149 (76) 169 (76)
Weight, kg 68 (68–71) 67 (58–80) 67 (58–78)
Systolic BP, mm Hg 129 (120–138) 136 (122–150) 135 (121–149)
Diastolic BP, mm Hg 67 (61–72) 70 (64–80) 70 (63–79)
Heart rate, beats per min-1 68 (60–77) 70 (62–78) 70 (61–79)
Atrial fibrillation, n (%) 20 (74) 138 (71) 158 (71)
Hypertension, n (%) 19 (70) 126 (65) 145 (65)
Hyperlipidemia, n (%) 12 (44) 84 (43) 96 (43)
Diabetes mellitus, n (%) 7 (26) 57 (29) 64 (29)
Smoking, n (%) 3 (11) 13 (7) 16 (7)
Heart valve procedures
Mitral valve repair, n (%) 5 (18) 21 (11) 26 (12)
Mitral valve replacement, n (%) 15 (56) 156 (80) 171 (77)
Aortic valve replacement, n (%) 14 (52) 90 (46) 104 (47)
Tricuspid valve surgery, n (%) 8 (30) 75 (39) 83 (37)
Mitral and aortic valve surgery, n (%) 7 (26) 72 (37) 79 (36)
Patients with reinterventions, n (%) 5 (19) 61 (31) 66 (30)
Time since last valvular surgery, y 9 (4–15) 7 (3–13) 7 (3–13)
Type of valve prosthesis, n (%)
Mechanical 22 (82) 153 (79) 175 (79)
Biological 3 (11) 36 (19) 39 (18)
Nominal size of prostheses, median (IQR)
Mitral 29 (27–29) 27 (25–29) 27 (25–29)
Aortic 21 (21–25) 21 (19–23) 21 (20–23)
Coronary artery revascularization
Coronary artery bypass graft, n (%) 0 (0) 13 (7) 13 (6)
Percutaneous coronary intervention, n (%) 0 (0) 12 (6) 12 (5)
Functional status
WHO functional classification, n (%)
I or II 22 (81) 111 (57) 133 (60)
III 5 (19) 84 (43) 89 (40)
6-min walk test distance, m 366 (318–410) 356 (270–408) 358 (272–408)
Concomitant mediations
Acenocoumarol or warfarin, n (%) 26 (96) 180 (92) 206 (93)
Aspirin, n (%) 1 (4) 19 (10) 20 (9)
Diuretics, n (%) 20 (80) 167 (86) 187 (84)
Aldosterone receptor antagonist, n (%) 11 (41) 83 (43) 94 (42)
ACE inhibitors, n (%) 11 (41) 77 (40) 88 (40)
Angiotensin II receptor blocker, n (%) 4 (18) 41 (21) 45 (20)
Laboratory
BNP, pg mL-1 40 (21–68) 59 (25–153) 55 (24–135)
Cardiac catheterization data
Right atrial pressure, mm Hg 10 (8–14) 12 (9–17) 12 (9–16)
Pulmonary artery oxygen saturation, % 66 (61–72) 64 (59–70) 64 (59–70)
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Statistical Analysis
All data are presented as median (interquartile 
range) except when otherwise indicated. We used 
multivariable imputation by chained equations for 
relevant missing data. We used the Pearson linear 
correlation coefficient (r) to assess the relationship 
between quantitative variables, and paired t tests to 
analyze the pre-/post-effects of the acute vasodila-
tor test. We used multivariable linear regression to 
address predictors of PVR. Survival data were right-
censored at 84 months and Kaplan-Meier plots and 
log-rank differences were calculated. The best cutoff 
values were obtained using maximally selected rank 
statistics implemented for survival analyses.16 The 
standardized mortality ratio (and its 95% CI) was cal-
culated comparing the cohort against the sex- and 
age-matched Spanish population for the studied 
period.17 We used univariable and multivariable Cox 
proportional hazards models to analyze survival. For 
multivariable models, we selected predictors based 
on the results of univariate analyses and then un-
derwent backwards stepwise selection using cross-
validation of 1000 replicates; only variables entered 
>50% of the replicates were retained. Identical vari-
ables were chosen in a sensitivity analysis performed 
using a purposeful selection strategy. For variable re-
duction of Doppler echocardiography data, we fitted 
a multivariable least-squares linear regression model 
using measured PVR as the dependent variable 
(Data S1 and Figure S1). The noninvasive surrogate of 
PVR was then entered in the Cox models instead of 
measured PVR. Bias-adjusted metrics of overall per-
formance of multivariable models was assessed cal-
culating the R2 and the C-statistic by bootstrapping 
1000 replicates. Proportional hazards assumptions 
were addressed by analysis of Schoenfeld residuals 
of each covariable and the global model. A cluster 
(random) effect of the recruiting center was excluded 
by mixed-effects Cox regression. For the validation 
analyses of 6-month end points, we also used the 
Kaplan-Meier method, log-rank tests and calculated 
their hazard ratios (HRs). We used R (version 4.0; The 
R Foundation) for all analyses and plots, and statisti-
cal significance was established at P<0.05.
Not Randomized Randomized Full Cohort
n= 27 n= 195 N= 222
Mean PAWP, mm Hg 17 (12–23) 22 (20–26) 22 (18–26)
Cardiac index, L min-1/m-2 2.7 (2.3–3.1) 2.8 (2.4–3.3) 2.8 (2.4–3.3)
Transpulmonary pressure gradient, mm Hg 9 (6–11) 16 (12–22) 15 (11–21)
Diastolic pressure gradient, mm Hg 1 (−2–4) 3 (0–7) 2 (0–6)
Pulmonary vascular resistance, WU 1.9 (1.3–2.7) 3.4 (2.3–5.0) 3.2 (2.1–4.8)
Pulmonary arterial compliance, mL/mm Hg-1 2.5 (2.1–3.1) 1.9 (1.3–2.5) 2.0 (1.4–2.7)
Pulmonary arterial elastance, mm Hg/mL 0.6 (0.5–0.8) 0.9 (0.7–1.2) 0.9 (0.7–1.2)
PH classification, n (%)
Precapillary PH 2 (7) 7 (4) 9 (4)
Isolated postcapillary PH 14 (52) 80 (41) 94 (42)
Combined postcapillary PH 2 (7) 108 (55) 110 (50)
All values are described as median (interquartile range) unless otherwise indicated. ACE indicates angiotensin-converting enzyme; BNP, brain natriuretic 
peptide; BP, blood pressure; IQR, interquartile range; PAWP, pulmonary artery wedge pressure; PH, pulmonary hypertension; WHO, World Health Organization; 
and WU, Wood units.
Table 1. Continued
Figure 2. Hemodynamic characterization at enrollment.
CpcPH indicates combined postcapillary pulmonary hypertension; 
IpcPH, isolated postcapillary pulmonary hypertension; PAWP, 
pulmonary capillary pressure; PH, pulmonary hypertension; and 
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RESULTS
Study Population
The present report is based on 222 patients of the 
231 initially entering the SIOVAC cohort (Figure 1). The 
median (interquartile range) age was 72 years (66–77 
years), 169 patients (76%) were women, and 64 pa-
tients (29%) had diabetes mellitus. The most frequent 
valvular surgery was mitral valve replacement (n=171, 
77%), and roughly one third of patients had undergone 
Table 2. Echocardiographic Data
Not Randomized Randomized Full Cohort
Total Population n=27 n=195 N=222
Available Data n=20 n=187 N=207
LV end-diastolic volume index, mL/m2 58 (42–68) 54 (44–64) 52 (43–63)
LV end-systolic volume index, mL/m2 22 (17–28) 22 (16–29) 21 (16–26)
LV ejection fraction, % 61 (54–62) 59 (54–64) 60 (55–63)
LV end-diastolic dimension, cm 49 (44–55) 50 (46–53) 50 (45–53)
Interventricular septum diastolic thickness, cm 1.0 (0.9–1.1) 1.1 (1.0–1.2) 1.0 (0.9–1.2)
RV end-diastolic area, cm2 20.9 (16.0–24.3) 19.9 (17.5–23.4) 19.8 (17.5–24.0)
RV end-systolic area, cm2 12.0 (9.2–13.4) 13.0 (10.7–14.9) 13.1 (11.1–15.5)
RV fractional area shortening, % 40 (40–50) 40 (30–40) 40 (30–40)
Right atrial area, cm2 23.1 (19.8–33.2) 22.7 (19.0–28.2) 23.1 (18.9–28.6)
Left atrial diameter, cm 5.2 (4.7–5.8) 5.0 (4.6–5.5) 5.1 (4.6–5.6)
Left atrial volume index, mL·m-2 89 (65–104) 91 (71–116) 90 (71–115)
Peak aortic jet velocity (native valve), m/s 1.8 (1.6–2.1) 1.9 (1.7–2.4) 1.9 (1.7–2.4)
Peak aortic jet velocity (prostheses), m/s 2.5 (1.9–3.2) 2.7 (2.3–3.1) 2.7 (2.3–3.1)
Effective aortic valve area index (prostheses), cm2/m2 0.96 (0.70–1.28) 0.88 (0.69–1.12) 0.88 (0.70–1.13)
Aortic valve patient-prosthesis mismatch (prostheses), n (%) 2 (18) 20 (24) 22 (23)
Aortic regurgitation, n (%)
0 11 (55) 94 (52) 105 (53)
I 8 (40) 67 (37) 75 (37)
II 1 (5) 19 (11) 20 (10)
Peak E wave velocity (native valve), m/s 1.6 (1.3–1.7) 1.6 (1.4–1.8) 1.6 (1.4–1.8)
Peak E wave velocity (surgical valve), m/s 1.9 (1.7–2.3) 2.0 (1.8–2.1) 2.0 (1.8–2.1)
Diastolic transmitral pressure gradient (surgical valve), mm Hg 5.0 (4.1–6.0) 4.9 (4.0–6.3) 4.9 (4.0–6.3)
E wave deceleration time (native valve), ms 301 (211–373) 179 (160–247) 205 (163–290)
E wave deceleration time (prostheses or repaired valve), ms 321 (224–354) 219 (186–287) 221 (188–299)
Effective mitral valve area index (prostheses or repaired), cm2·m-2 0.92 (0.86–1.14) 1.05 (0.83–1.18) 1.04 (0.83–1.18)
Mitral valve patient-prosthesis mismatch (prostheses or repaired), n (%) 8 (66) 126 (79) 134 (78)
Mitral regurgitation, n (%)
0 14 (70) 106 (59) 120 (60)
I 5 (25) 48 (27) 53 (27)
II 1 (5) 26 (14) 27 (13)
Tricuspid annular plane systolic excursion, cm 1.7 (1.5–2.0) 1.5 (1.2–1.7) 1.5 (1.3–1.8)
Tricuspid regurgitation, n (%)
0 0 (0) 1 (1) 1 (1)
I 5 (25) 18 (10) 23 (12)
II 8 (40) 99 (56) 107 (54)
III 7 (35) 50 (28) 57 (29)
IV 0 (0) 9 (5) 9 (5)
Pulmonary flow acceleration time, ms 96 (81–112) 69 (60–83) 69 (60–83)
Tricuspid jet peak regurgitant velocity, m/s 3.0 (2.7–3.2) 3.5 (3.2–3.9) 3.5 (3.2–4.0)
Estimated pulmonary systolic arterial pressure, mm Hg 46 (38–53) 61 (53–72) 61 (53–76)
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more than 1 valve procedure (Table 1). Most patients 
(n=214, 93%) had mechanical prostheses. Among 
these, 85% were of bileaflet design.
Catheterization and Echocardiographic 
Profiling
Baseline hemodynamic results showed significant 
elevation in mPAP and PAWP (37 mm  Hg [32–44 
mm  Hg] and 23 mm  Hg [18–26 mm  Hg], respec-
tively), whereas cardiac index was in the low-nor-
mal range (Table 1, Figure 2). Median PVR was 3.2 
WU (2.1–4.8 WU). One half of the study population 
(n=110) experienced combined postcapillary PH, 
whereas 94 patients (42%) experienced isolated 
postcapillary PH. Of the remaining 18 patients 
showing a PAWP <15 mm Hg, precapillary PH was 
present in 9 (4%). Results of acute vasodilator tests 
are summarized in Data S1.
Median LV ejection fraction was 60% (55%–63%) 
and only 34 patients (15%) showed values  <50% 
(Table 2). Almost all patients had mild or moderate 
degrees of tricuspid regurgitation and tricuspid an-
nular plane systolic excursion was in the low lim-
its. Mitral prosthesis mismatch was found in 78% 
of patients with previous mitral surgery and avail-
able ultrasound data. These patients showed higher 
values of PVR, as PVR inversely correlated with ef-
fective mitral valve area index (r=−0.28, P=0.0002; 
Table 3). Multivariable regression showed that PVR 
was directly related to the presence of diabetes 
mellitus (β=0.9 WU, P=0.005) and inversely related 
to mitral and aortic valve area indices (β=−1.5 WU 
and 0.8 WU per cm2/m2 [P=0.003 and P=0.048], re-
spectively). In turn, valve area index correlated with 
nominal size, both of mitral (r=0.30, P=0.001) and 
aortic (r=0.32, P=0.005) prostheses.
Survival
During the follow-up period (median 4.5 years [3.3–6.4 
years]), 91 deaths were recorded (41%). Causes of 
death were cardiovascular in 70 (78%), noncardiovas-
cular in 15 (16%), and undetermined in 6 (7%) patients. 
Cardiovascular deaths were of cardiac origin in 52 pa-
tients (end-stage heart failure in 42, sudden cardiac 
death in 5, acute myocardial infarction in 2, and other 
events in 3), fatal hemorrhagic events in 15, and ischemic 
stroke in 3. Median overall survival rates at 12, 24, and 
60 months were 0.95 (95% CI, 0.92–0.98), 0.86 (95% CI, 
0.81–0.90), and 0.62 (95% CI, 0.55–0.69), respectively 
(Figure 3A). Compared with the Spanish age-matched 
population, the standardized mortality ratio was 4.21 
(95% CI, 3.43–5.17; P<0.0001). Kaplan-Meier curves for 
cardiovascular mortality and stratification according to 
the enrollment group are shown in Figure 3B and 3C. In 
randomized patients, 6-month exposure to the investiga-
tion drug was unrelated to long-term survival (HR, 0.81; 
95% CI, 0.52–1.25 [P=0.34], sildenafil versus placebo).
Survival Predictors
Demographic, clinical, catheterization, and echocar-
diographic factors were related to all-cause mortal-
ity (Table  4). Multivariable analyses (Table  5) showed 
that the most determinant risk factor for mortality was 
male sex (HR, 1.92; 95% CI, 1.20–3.08). Age, diabetes 
mellitus, and functional class were related to mortality. 
Among catheterization variables, mPAP, transpulmo-
nary pressure gradient, pulmonary arterial elastance, 
and PVR were all related to survival (Table 4; Figure 4). 
However, the latter was the only catheterization vari-
able entering multivariable prediction models (HR, 
1.10; 95% CI, 1.01–1.19 per WU [P=0.04]). Neither the 
hemodynamic PH classification nor the response to 
the acute vasodilator test predicted survival (Table 4, 
Figure  3D). Among echocardiographic variables, the 
estimated PSAP, tricuspid annular plane systolic excur-
sion, and transmitral pressure gradient were all related 
to survival (Table  4), but no echocardiographic vari-
able alone added predictive value to clinical factors in 
multivariable models. Echocardiographic data yielded 
a relatively accurate estimate of PVR by multivariable 
linear regression (Figure 5). This noninvasive estimate 
of PVR was the most powerful predictor of all-cause 
mortality in the multivariable model (HR, 1.25; 95% 
CI, 1.06–1.42 per 1 noninvasive WU). Optimal thresh-
olds of PVR and noninvasive PVR to predict all-cause 
mortality were identical: 4.3 WU. Performance of the 
3 multivariable models (clinical, clinical+catheterization, 
and clinical+ultrasound) to predict survival was nearly 
identical (bootstrapped C-index: 0.67 to 0.68, Table 5). 
Survival curves for the most relevant predictors of all-
cause mortality are shown in Figure 6. Demographic, 
clinical, catheterization, and ultrasound predictors 
Table 3. Correlation Analyses of Factors Related to PAWP 
and PVR
PAWP PVR
Mitral mean transvalvular pressure 
gradient§
0.21* −0.05
Mitral valve area index§ −0.05 −0.28*
Mitral prosthesis-patient mismatch 
(no vs yes)§
22 vs 22 mm Hg 2.8 vs 3.9 WU*
Aortic mean transprosthetic 
pressure gradient
0.20* −0.10
Aortic prosthetic valve area index −0.26* 0.03
Aortic prosthesis-patient mismatch 
(no vs yes)†
22 vs 23 mm Hg 3.1 vs 3.9 WU
Values represent Pearson correlation coefficient (r), except †, which shows 
mean values for either group. PAWP indicates pulmonary artery wedge 
pressure; PVR, pulmonary vascular resistance; and WU, Wood units.
*P<0.05.
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related to cardiovascular mortality were similar to those 
related to all-cause mortality (Table 6).
The composite clinical score and changes in 
6MWT distance evaluated at 6  months performed 
relatively well to predict survival, whereas the change 
in brain natriuretic peptide levels performed worse 
(Figure  7; bootstrapped C-indices: 0.62, 0.57, and 
0.52, respectively).
Figure 3. Survival curves of the study cohort.
(A) Global survival of the full cohort compared with the Spanish age-matched control population. (B) Survival without cardiovascular 
mortality. (C, D) Stratification based on the role in the clinical trial and pulmonary hypertension (PH) classification group, respectively. 
CpcPH indicates combined postcapillary pulmonary hypertension; IpcPH, isolated postcapillary pulmonary hypertension; mPAP, 
mean pulmonary arterial pressure; PH, pulmonary hypertension; SIOVAC Sildenafil for Improving Outcomes After Valvular Correction; 
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DISCUSSION
In the largest prospective cohort of patients with in-
vasively documented persistent VHD-PH reported 
so far, we demonstrate that the long-term survival of 
this condition is poor. In most cases, this complica-
tion is related to a chronic elevation of left-sided heart 
pressures, with only 4% of patients showing precap-
illary PH according to current definitions. Men with 
diabetes mellitus in World Health Organization (WHO) 
functional class III and a PVR >4.3 WU—either meas-
ured by catheterization or estimated using echocardi-
ography—are patients at highest risk for dying. These 
findings have important implications for understanding 
Table 4. Univariate Predictors of Mortality
HR 95% CI P Value
Clinical
Age (per 10 y) 1.65 1.24–2.19 0.0006
Men 1.72 1.09–2.70 0.018
Diabetes mellitus 2.10 1.39–3.18 0.0005
WHO functional class III vs I or II 2.08 1.38–3.14 0.0005
Time from last surgery (per y) 1.00 0.98–1.03 0.57
6MWT distance (per 50 m) 0.83 0.75–0.93 0.0008
BNP (per 1 log pg mL-1) 1.27 1.05–1.53 0.01
Catheterization
mPAP (per 10 mm Hg) 1.34 1.08–1.65 0.007
PAWP (per 10 mm Hg) 1.21 0.82–1.77 0.34
TPG (per 1 mm Hg) 1.04 1.01–1.06 0.009
DPG (per 1 mm Hg) 1.02 0.99–1.06 0.25
TPG >12 mm Hg (binary) 1.38 0.87–2.18 0.17
PVR (per 1 WU) 1.12 1.03–1.22 0.007
PVR >3 WU (binary) 1.19 0.79–1.81 0.40
PAC (per 1 mL/mm Hg) 1.00 0.87–1.17 0.96
Pulmonary arterial elastance (per 1 mm Hg/mL) 1.70 1.10–2.63 0.016
Acute vasoreactivity test
Delta CO (per increase 0.5 mL/min) 1.04 0.89–1.22 0.58
Delta PVR (per decrease 0.5 WU) 1.00 0.90–1.11 0.98
Delta PAC (per increase 0.5 mL/mm Hg) 1.08 0.89–1.31 0.41
Echocardiography
LV ejection fraction (per 10%) 0.95 0.74–1.21 0.65
RV fractional area change (per 10%) 0.87 0.70–1.09 0.22
RV end-diastolic area (per 5 cm2) 1.05 0.85–1.29 0.65
RV end-systolic area (per 5 cm2) 1.18 0.87–1.59 0.29
Right atrial area (per 5 cm2) 1.03 0.92–1.16 0.62
Tricuspid annular plane systolic excursion (per 0.5 cm) 0.71 0.53–0.97 0.031
Mean diastolic transmitral pressure gradient (per 1 mm Hg) 1.10 1.01–1.19 0.025
Transmitral velocity deceleration time (per 100 ms) 0.89 0.69–1.16 0.38
Prosthetic/repaired mitral valve area index (per 0.5 cm2/m-2) 1.08 0.76–1.53 0.66
Prosthetic aortic valve area index (per 0.5 cm2/m-2) 0.97 0.71–1.32 0.87
Pulmonary acceleration time (per 10 ms) 0.93 0.84–1.03 0.16
Tricuspid regurgitation (per 1 degree) 0.92 0.68–1.25 0.60
Peak TR jet velocity (per 1 m/s) 1.31 1.08–1.59 0.005
Estimated PSAP (per 10 mm Hg) 1.17 1.04–1.33 0.01
Estimated PVR (per 1 WU) 1.23 1.06–1.42 0.007
6MWT indicates 6-minute walk test; BNP, brain natriuretic peptide; CO, cardiac output; DPG, diastolic pulmonary gradient; HR, hazard ratio; LV, left 
ventricular; mPAP, mean pulmonary arterial pressure; PAC, pulmonary arterial compliance; PAWP, pulmonary artery wedge pressure; PSAP, pulmonary artery 
systolic pressure; PVR, pulmonary vascular resistance; RV, right ventricular; TPG, transpulmonary pressure gradient; TR, tricuspid regurgitation; WHO, World 
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the foundations of persistent VDH-PH as well as for its 
potential prevention.
Understanding Persistent VHD-PH
Unlike in other causes of LHD-PH, the causative left-
sided heart lesion is usually corrected in persistent 
VHD-PH, and only in 15% of patients showed LV sys-
tolic dysfunction in our series. It is classically believed 
that valvular hemodynamics return to normal after cor-
rection of the valvular lesion and that LV systolic dys-
function is prevented when valvular interventions are 
accurately timed. Because patients with preoperative 
PH frequently do not have normalized pulmonary pres-
sure after surgery, the focus has been usually placed 
on preoperative vascular damage.5,8,18 Therefore, PH 
in operated valvular patients is frequently designated 
“residual PH,” attributing PH to irreversible changes in 
arterial and arteriolar pulmonary vessels caused by de-
layed surgery.19,20
Our finding of almost universal PAWP elevation in 
most patients with VHD-PH challenges this interpre-
tation. The foundations of a chronic elevation of PAWP 
remain unknown, but factors such as functionally 
restrictive valves (see below),5 LV diastolic dysfunc-
tion, and progressive vascular remodeling at the 
arteriolar, undetermined, and venular vessels21 may 
be involved. In addition, the high prevalence of atrial 
fibrillation and the large atrial volumes observed in 
our cohort support a potential role of atrial dysfunc-
tion.22 Some authors have suggested the early role 
of reactive increase in pulmonary arterial tone related 
to neurohormonal (eg, endothelin-mediated) and 
neurogenic mechanisms.23 This functional impair-
ment could be unmasked by the response to acute 
vasodilation tests, which, in theory, would be able 
to discriminate (early) “reversible” from (late) “fixed” 
mechanisms of precapillary and combined postcap-
illary PH. However, the results of our study show no 
long-term prognostic value of acute or chronic use 
of sildenafil.12 These findings further advise against 
the indiscriminate use of vasoreactivity tests in fields 
other than specific causes of group 1 PH.1
Survival of Patients With Persistent VHD-PH
Survival in patients with persistent VHD-PH was 62% 
at 5  years, and all-cause mortality was 4.2 times 
Table 5. Multivariable Models of Any-Cause Mortality
Model Variable HR 95% CI Χ 2 P Value
Clinical
Sex (male vs female) 1.92 1.20–3.08 7.42 0.006
Age (per 10 y) 1.49 1.11–2.01 7.04 0.008
Diabetes mellitus 1.69 1.10–2.59 5.68 0.01
WHO functional class 
III vs I or II
1.62 1.05–2.53 4.64 0.03
6MWT distance (per 
50 m)
0.92 0.82–1.04 2.65 0.10
Bootstrapped R2=0.13; C-index=0.67
Clinical+catheterization
Age (per 10 y) 1.56 1.17–2.09 8.96 0.011
WHO functional class 
III vs I or II
1.76 1.15–2.68 6.87 0.008
Sex (male vs female) 1.82 1.15–2.87 6.50 0.011
Diabetes mellitus 1.70 1.11–2.61 5.97 0.014
PVR (per 1 WU) 1.10 1.01–1.19 4.02 0.04
Bootstrapped R2=0.13; C-index=0.67
Clinical+echocardiography
Predicted PVR (per 
1 WU)
1.25 1.06–1.46 7.52 <0.001
WHO functional class 
III vs I or II
1.82 1.14–2.92 6.33 0.011
Age (per 10 y) 1.44 1.05–1.98 5.17 0.02
Sex (male vs female) 1.73 1.03–2.92 4.26 0.04
Diabetes mellitus 1.47 0.91–2.37 2.53 0.11
Bootstrapped R2=0.14; C-index=0.68
For each model, predictors are sorted by their statistical relevance. 6MWT indicates 6-minute walk test; HR, hazard ratio; PVR, pulmonary vascular resistance; 
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higher than in the matched population. Compared 
with global cohorts of group 2 PH, this survival rate 
is close to rates previously reported in some groups4 
but markedly lower than the standard mortality ratio 
7.1 value reported by others.2 It is also similar to the 
mortality rate of patients with heart failure,24,25 but 
it doubles the mortality rate of unselected carriers 
of mechanical valve prostheses (standard mortality 
ratio, 1.74–1.99).26 More than two thirds of our co-
hort were women, and female sex was associated 
with a better prognosis, 2 typical findings of other 
causes of PH,27 and persistent VHD-PH.5 The high 
prognostic value we observed for WHO functional 
class III and 6MWT distance underscores the role 
of functional characterization of patients with PH. 
Importantly, clinical variables yielded the most useful 
prognostic information.
A unique characteristic of our cohort is its exhaus-
tive characterization by right-sided cardiac catheter-
ization. Inconsistent with other LHD-PH reports,28,29 
neither PAWP nor the PH group classification were 
related to mortality. This lack of association may be 
attributable to the fact that elevated PAWP in VHD is 
not an indicator of advanced LV systolic or diastolic 
dysfunction.29 In our cohort, the PVR cutoff value for 
predicting survival was 4.3 WU, slightly higher than the 
3.0 WU threshold that defines combined postcapillary 
PH in current guidelines.14 This higher cutoff explains 
why PH classification was not related to outcomes in 
our series, and, again, emphasizes the singularity of 
this condition. As in other cohorts, we found no rela-
tionship between the diastolic pressure gradient and 
outcomes.28,30
Among the Doppler echocardiographic variables, 
tricuspid annular plane systolic excursion, the trans-
prosthetic mitral pressure gradient, and peak tricus-
pid regurgitation jet velocity correlated with survival. 
Remarkably, tricuspid regurgitation was not related to 
mortality, in concordance with recent observations.31 
Echocardiographic variables added no prognostic infor-
mation to clinical and demographic data in univariable 
modeles. Instead, clustered as estimated PVR, they 
were significantly related to global and cardiovascular 
survival.
Figure 4. The relationship between pulmonary vascular 
resistance (PVR) and outcomes.
(A) Kaplan-Meir survival curves based on the PVR quartile 
distribution. (B) Per-quartile hazard ratio (HR) analysis. When 
analyzed by quantiles of the distribution, only quartile 4 vs 
quartile 1 was significant (HR not including 1), without significant 
differences in the intermediate categories.
Figure 5. Results of the multivariable regression fitting 
for predicting pulmonary vascular resistance (PVR) from 
ultrasound data.
AccTimePV indicates Doppler acceleration time as measured 
by pulsed-wave Doppler at the level of the pulmonary valve 
(ms); BSA, body surface area (m2); HR, heart rate (min-1); PVR, 
pulmonary vascular resistance (Wood units [WU]); SysDTI_RV, 
peak systolic myocardial velocity as measured by Doppler 
tissue imaging of the right ventricular free wall (cm/s); TVILVOT, 
left ventricular outflow-tract pulsed-wave Doppler time velocity 
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Clinical Implications for Preventing PH 
and its Consequences
In the present article, we identified procedural issues 
that have a direct impact on outcomes. Diabetes mel-
litus was particularly deleterious, not only because 
of its direct impact on survival but also because it 
showed an additive effect on PVR. Although the inter-
action between diabetes mellitus and LHD-PH is not a 
novel finding,32–35 its potential implications in VHD-PH 
had not been reported. A significant number of pa-
tients in our cohort met the criterion of patient-valve 
Figure 6. Kaplan-Meier overall-survival curves based on most relevant predictors.
Stratification based on sex (A), World Health Organization (WHO) functional class (B), and pulmonary vascular resistance (PVR), either 
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mismatch (>79% of patients with mitral disease), and 
effective residual valve area was inversely related 
with PVR. These observations constitute an invasive 
and long-term confirmation of prior Doppler-based 
reports relating prosthesis-patient mismatch and re-
strictive annuloplasties to persistent VHD-PH.5,7,36 As 
expected, effective valve area was, in turn, related to 
prosthetic nominal size. In consequence, whenever 
possible, mitral valve repair should be preferred over 
replacement, but restrictive annuloplasties should be 
avoided. Prostheses with sizes and designs showing 
the largest functional areas are preferable but may 
require more complex surgical techniques. Thus, pro-
cedural risks must be carefully balanced, keeping in 
mind that based on the results of our study, elderly 
patients and those with diabetes mellitus are at the 
highest risk of the consequences of persistent PH. 
Furthermore, adequate sizing of prostheses should 
not be overlooked in men, despite their larger body 
surface area. For aortic valve procedures, transcath-
eter aortic valves yield larger effective area than their 
surgical sutural equivalents.
If PH is suspected at least 1 year after the primary 
valvular lesion has been corrected, patients should 
undergo a comprehensive workup. Valvular dysfunc-
tion must be ruled out in the first place. Noninvasive 
estimates of PVR and pulmonary pressures should be 
obtained, but a right-sided catheterization procedure 
ought to characterize the hemodynamic substrate. 
Patients should be closely followed, and aggressive 
therapeutic interventions may occasionally be con-
sidered, particularly in men with diabetes mellitus, as 
well as in patients with functional class III or PVR val-
ues >4.3 WU. The observation of a direct relationship 
between walking distance and survival suggests a 
potential benefit of cardiac rehabilitation.37 Treatment 
options for these patients must be further studied, 
and the survival rates described herein are a suitable 
reference to balance their risks. For future clinical tri-
als in the field, our results support 6-month changes 
in the composite clinical score and in 6MWT distance 
as valid end points. However, longer-term studies 
with clinical end points continue to be preferred for 
phase 3 studies.
Table 6. Multivariable Models of Cardiovascular Mortality
Model Variable HR 95% CI Χ 2 P Value
Clinical
Sex (male vs female) 2.43 1.45–4.08 11.45 0.0007
Age (per 10 y) 1.47 1.05–2.05 5.02 0.025
6MWT distance (per 
50 m)
0.86 0.75–0.98 4.91 0.03
WHO functional class 
III vs I or II
1.57 0.94–2.60 3.03 0.08
Diabetes Mellitus 1.31 0.79–2.16 1.09 0.30
Bootstrapped R2=0.11; Dxy=0.36; C-index=0.68
Clinical+catheterization
Sex (male vs female) 2.16 1.31–3.59 8.98 0.003
Age (per 10 y) 1.58 1.14–2.19 7.41 0.007
WHO functional class 
III vs I or II
1.81 1.12–2.93 5.90 0.02
PVR (per 1 WU) 1.10 1.01–1.19 3.90 0.05
Diabetes mellitus 1.93 0.85–2.30 1.71 0.19
Bootstrapped R2=0.10; Dxy=0.34; C-index=0.67
Clinical+echocardiography
Sex (male vs female) 2.17 1.20–3.92 6.59 0.01
WHO functional class 
III vs I or II
1.87 1.08–3.25 4.98 0.03
Predicted PVR (per 
1 WU)
1.24 1.02–1.50 4.81 0.03
Age (per 10 y) 1.45 1.00–2.08 3.95 0.05
Diabetes mellitus 1.09 0.60–1.96 0.08 0.78
Bootstrapped R2=0.08; Dxy=0.27; C-index=0.64
For each model, predictors are sorted by their statistical relevance. 6MWT indicates six-minute walk test; HR, hazard ratio; PVR, pulmonary vascular 
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Study Limitations
Data on the primary valvular lesions and hemodynamic 
profiles immediately before and after surgery were 
unavailable, precluding a longitudinal picture of PH in 
these patients. However, the period elapsed from the 
last surgery to recruitment was long (median 7 years), 
almost one third of the cohort had undergone prior rein-
terventions, and the finding of high PAWPs was almost 
universal. These issues suggest that postcorrection 
factors are the major determinants of outcomes in pa-
tients with persistent VHD-PH. Because the SIOVAC 
cohort was recruited for participating in a clinical trial, 
we cannot exclude certain selection bias toward more 
severe disease. Median mPAP of the full study cohort 
was 37 mmHg, far above the cutoff of 20 mm Hg now 
established as PH diagnostic criterion.14 Therefore, re-
sults should be extrapolated with caution to milder de-
grees of PH. The multivariable ultrasound PVR model 
was calculated and validated in the same sample. Even 
though bootstrapping was used to palliate overfitting, 
future studies are needed. Finally, pulmonary functional 
tests were not performed and, therefore, a combination 
of group 2 and group 3 PH causes cannot be excluded 
in some patients. However, the infrequent usage of 
bronchodilator medications suggests a low prevalence 
of pulmonary disease in the cohort.
CONCLUSIONS
Elevated left-sided heart pressures play a major role 
in persistent VHD-PH. Mortality of patients with per-
sistent VHD-PH is more than 4 times higher than in 
the age- and sex-matched general population. Risk 
factors for mortality in patients with this condition 
are age, male sex, diabetes mellitus, advanced func-
tional class, and high PVR—measured by cardiac 
catheterization or approximated using ultrasound. 
Patients with diabetes mellitus and those with small 
valve prostheses show the worst hemodynamic pro-
files. These findings present an opportunity for pre-
venting this complication.
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Amorós Galitó. 
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Concepción Belló Mora, Dolores Mesa Rubio. 
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Supplemental Methods 
Because no single echocardiographic variable was related to survival in the 
multivariable model, we underwent a variable-reduction strategy to cluster Doppler-
echocardiographic variables into a single metric. For this purpose, we underwent a multivariable 
linear regression model to predict PVR, as measured by cardiac catheterization. Combining 
ultrasound variables shown in Table 2 with other relevant noninvasive information we 
underwent automatic variable selection by cross-validation backwards selection algorithm using 
1,000 replicates. Predicted values of PVR estimated noninvasively were then entered in the uni 
and multivariable Cox proportional-hazard models to predict survival. 
Supplemental Results 
The acute vasoreactivity test (n= 140) induced significant reductions in PAWP (mean 
decrease -1.1 mm Hg, p= 0.003), mPAP (-3.3 mm Hg, p< 0.0001), and PVR (-0.6 W.U, p< 
0.0001), without significantly changing cardiac output (-0.46 l/min, p= 0.22), and significantly 
increasing PAC (+0.46 mL/mm Hg; Figure S1). Despite these changes, the impact of sildenafil 
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Values for each patient with available data are shown for baseline (red) and post-sildenafil (100 
mg, sublingual) connected by a dotted line. Global effects for the full cohort are shown in the 
marginal boxplots.  
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